SEOUL (Reuters) – South Korea’s Celltrion Inc on Thursday said British regulators had given it regulatory approval for a phase I clinical trial of its experimental COVID-19 treatment drug.
The company will enrol participants for a clinical study in the UK after approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), Celltrion said in a statement.
South Korean regulators on July 17 approved an early stage clinical trial for the drug, making it the country’s first such antibody drug to be tested on humans.
(Reporting by Sangmi Cha; Editing by Tom Hogue)
